



FOR IMMEDIATE RELEASE

## More Than 75 Companies Adopt Veeva Vault CTMS to Accelerate Clinical Research

*Vault CTMS simplifies end-to-end trial management for greater visibility and speed in trials*

**PLEASANTON, CA — Nov. 11, 2020** — As the need to improve efficiency and speed in trials grows, more than 75 organizations, including six of the top 20 pharmaceutical companies, are unifying clinical information and processes with **Veeva Vault CTMS**. More emerging biotechs and global organizations have adopted the modern cloud application from **Veeva Systems** (NYSE: VEEV) for greater visibility and faster execution in trials. Sponsors and clinical research organizations (CROs) are using Vault CTMS to manage nearly 50,000 clinical trials across all study phases.

“The widespread use of siloed systems and spreadsheets to manage clinical trials have been slowing down studies for years,” said Henry Galio, senior director, Veeva Vault CTMS. “Companies are standardizing on Veeva Vault CTMS for real-time insights into study status to proactively manage trials and speed research.”

Legacy systems are difficult to use and configure, adding complexity to trials, and slowing study execution. Companies that use modern CTMS applications report better compliance with standards, greater visibility, and improved governance and oversight than those using manual-based spreadsheets or internally developed systems to manage studies.<sup>1</sup>

Vault CTMS streamlines end-to-end trial management for improved collaboration and increased transparency across trials. Sponsors and CROs can proactively identify obstacles and take corrective action to avoid delays. Now clinical teams can keep trials on track and better meet study milestones while maintaining compliance with ICH/GCP guidelines.

Veeva continues to bring innovations to market that simplify clinical processes. Over the last year, Veeva has added new capabilities to help customers proactively manage trials and adapt quickly to changes, including:

- **Vault Payments**, an application to manage the payment and reimbursement of research sites;
- Seamless integration with **Veeva Vault EDC** for improved visibility and reporting;
- The ability for CRAs to quickly and easily author monitor trip reports for improved productivity and efficiency.

Vault CTMS is part of **Veeva Vault Clinical Operations Suite**, enabling sponsors and CROs to seamlessly share information and documents across CTMS, eTMF, and study start-up for better collaboration and increased efficiency throughout the study lifecycle.

AstraZeneca discusses the positive impact of a unified clinical landscape on global study execution at the Veeva R&D and Quality Summit, register for the on-demand session at [veeva.com/rds Summit](https://veeva.com/rds Summit).

### Additional Information

For more on Veeva Vault CTMS, visit: [veeva.com/CTMS](https://veeva.com/CTMS)

Connect with Veeva on LinkedIn: [www.linkedin.com/company/veeva-systems](https://www.linkedin.com/company/veeva-systems)

Follow @veevasystems on Twitter: [www.twitter.com/veevasystems](https://www.twitter.com/veevasystems)

Like Veeva on Facebook: [www.facebook.com/veevasystems](https://www.facebook.com/veevasystems)

### About Veeva Systems

Veeva Systems Inc. is a leader in cloud solutions—including data, software, and services—for the

---

<sup>1</sup> Veeva Systems, **2020 Unified Clinical Operations Survey Report**, 2020

global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 900 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. The company is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit [veeva.com](http://veeva.com).

### **Forward-looking Statements**

This release contains forward-looking statements, including the market demand for and acceptance of Veeva's products and services, the results from use of Veeva's products and services, and general business conditions (including the on-going impact of COVID-19), particularly within the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva's historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva's expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva's financial results are included under the captions, "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations," in the company's filing on Form 10-Q for the period ended July 31, 2020. This is available on the company's website at [veeva.com](http://veeva.com) under the Investors section and on the SEC's website at [sec.gov](http://sec.gov). Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.

###

### **Contact:**

Roger Villareal  
Veeva Systems  
925-264-8885  
[roger.villareal@veeva.com](mailto:roger.villareal@veeva.com)

Deivis Mercado  
Veeva Systems  
925-226-8821  
[deivis.mercado@veeva.com](mailto:deivis.mercado@veeva.com)